Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Imugene ( (AU:IMU) ) is now available.
Imugene Limited has notified the market of the cessation of several classes of equity-linked securities, including more than 5.8 million options expiring on 31 March 2026 that lapsed unexercised. Additional options and restricted stock units, totaling over 1.2 million securities, also lapsed on 31 March 2026 because vesting or performance conditions were not met or became incapable of being satisfied.
The announcement reflects a reduction in Imugene’s potential future share dilution, as these options and rights will no longer convert into ordinary shares. This change simplifies the company’s capital structure and may modestly alter the value of remaining equity, with implications for existing shareholders and for participants in the company’s incentive schemes whose awards have now expired or lapsed.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited, listed on the ASX under the code IMU, is a biotechnology company focused on developing immuno-oncology therapies for cancer treatment. The company issues various equity-linked securities, including options and restricted stock units, as part of its capital management and incentive structures for investors and employees.
Average Trading Volume: 1,627,036
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$53.55M
See more insights into IMU stock on TipRanks’ Stock Analysis page.